ELYSE HAMMETT: Open Payments
NPI 1831103159 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$471 in 23 payments from 10 companies in 2025. Trend: 2023 $1 · 2024 $521 · 2025 $471
Food & beverage: $471
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $142 |
| Ardelyx, Inc. | 3 | $86 |
| Madrigal Pharmaceuticals | 3 | $84 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Gilead Sciences, Inc. | 1 | $22 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
Products named: IBSRELA, REZDIFFRA, RINVOQ, LINZESS, IQIRVO, DUPIXENT, SKYRIZI, VOQUEZNA.
Industry payments across AZ — which companies pay providers there.
